BioSpace News Archive

Kuros Biosciences, a leader in next generation bone healing technologies, announced the publication of a peer-reviewed manuscript that details the clinical data of its MAXA Level 1 prospective, multi-center, randomized, intra-patient controlled clinical study in Spine 1.

Ethris GmbH announced preliminary positive data from its Phase 1 dose escalation clinical trial evaluating the safety, tolerability, and target engagement of lead mRNA candidate ETH47 encoding interferon lambda, in healthy participants.

IDEAYA Biosciences, Inc. announced that it has dosed its first patient in the IDEAYA-sponsored Phase 1 trial evaluating the combination of IDE397, IDEAYA’s investigational MAT2A inhibitor, and Trodelvy®, Gilead’s Trop-2 directed ADC, in patients with MTAP-deletion bladder cancer.

Zomedica Corp. announced it has secured the CE mark for its proprietary point-of-care TRUFORMA Bulk Acoustic Wave diagnostic platform.

Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL) today announced initial results from the Phase 1 clinical trial evaluating WTX-330, its conditionally activated interleukin-12 (IL-12) INDUKINE™ molecule, as monotherapy in patients with immunotherapy insensitive or resistant locally advanced or metastatic solid tumors or non-Hodgkin lymphoma.

BioXcel Therapeutics, Inc. today announced positive topline results from a post-marketing requirement (PMR) study of IGALMI™ (dexmedetomidine) sublingual film that demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with the 180 mcg dose after seven days of PRN (as-needed) treatment.

Cellens, Inc., an early-stage cancer diagnostic company pioneering in applying mechanobiology and machine learning analysis announced that it is collaborating with Bruker BioAFM, a business unit of Bruker, to develop the world’s first clinical diagnostic tests that leverage multi-parametric, single-cell biophysical markers and machine learning.

Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in real-time iCMR cardiac ablation products, is pleased to announce that the Vision-MR Ablation Catheter 2.0 for Treatment of Type I Atrial Flutter (VISABL-AFL) IDE clinical trial, commenced with two procedures performed at the Cardiovascular Institute of South Paris (ICPS) (https://icps.fr).

MOMA Therapeutics today announced the appointments of two seasoned industry executives to the company’s leadership team. Marc Ballas, M.D., joins as SVP, head of clinical development, and Adam Thomas joins as chief people and experience officer.

Switch Therapeutics today announced that Dee Datta, Ph.D., co-founder and CEO of Switch Therapeutics, will present and host investor meetings at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on Thursday, June 27, 2024.